United Medical

Vision: To become a leader in precision prevention. Product layout across four major platforms: Fluorescence Quantitative PCR Platform (rapid diagnostic solutions for multiple pathogens in infectious diseases and maternal and child health), Flow Cytometry Platform (enabler of multi-omics monitoring for infectious immunity), Fluorescence Scanning and Analysis Platform (pioneer in AI-intelligent diagnosis of gynecological inflammation and fungal infections), and High-Throughput Sequencing Platform (targeted pathogen sequencing and newborn genetic screening).
Mission: To drive technological innovation, popularize high-quality molecular diagnostic technologies, and continuously create value for life and health.
Founded in 2011, it is a mature and stable IVD enterprise. Over 30% of the R&D team holds master's degrees, with 3 Ph.D. holders, and 3 Shenzhen Peacock Talents and high-level talents. It has rich research and development experience and talent reserves in molecular diagnostic technology, bioinformatics analysis, and genetic counseling. Technological innovation: In 2016, it was recognized as a National High-Tech Enterprise; in 2021, it was approved as the "Guangdong Provincial Engineering Technology Center for Multi-Omics Precision Diagnosis of Infectious Diseases"; in 2022, it was selected as a National Specialized and Sophisticated "Little Giant". It has carried out scientific research cooperation with multiple institutions and clinical units including the Wuhan Institute of Virology of the Chinese Academy of Sciences, Hong Kong University of Science and Technology, Shenzhen University, and Shenzhen Center for Disease Control and Prevention. It has undertaken multiple major projects and research topics such as emergency research projects of the Ministry of Science and Technology, Shenzhen Sustainable Development projects, and industrialization projects of the Shenzhen Development and Reform Commission.
It has 22 authorized patents and 13 software copyrights, with 21 patents currently under application. Product market: It has a mature and complete medical device production and registration system. Its quality system has obtained ISO9001 and ISO13485 certifications through SGS in the European Union. Multiple products have obtained Class II and Class III medical device registration certificates issued by the U.S. FDA, EU CE, and the National Medical Products Administration. It has a complete domestic and international marketing network, with products sold in batches to over 20 countries and regions including the European Union, Asia-Pacific, and Latin America. Its COVID-19 nucleic acid testing products have won bids in centralized procurement of COVID-19 testing reagents in the "Beijing-Tianjin-Hebei" region, the Guangdong 18-Province Alliance, Henan Province, Sichuan Province, and other provinces.